S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:CTSO

Cytosorbents (CTSO) Stock Price, News & Analysis

$0.95
+0.02 (+2.15%)
(As of 03/28/2024 ET)
Today's Range
$0.87
$0.96
50-Day Range
$0.86
$1.04
52-Week Range
$0.84
$4.29
Volume
116,409 shs
Average Volume
174,156 shs
Market Capitalization
$51.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.50

Cytosorbents MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
163.2% Upside
$2.50 Price Target
Short Interest
Healthy
3.08% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.46) to ($0.21) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.51 out of 5 stars

Medical Sector

733rd out of 938 stocks

Surgical & Medical Instruments Industry

77th out of 94 stocks

CTSO stock logo

About Cytosorbents Stock (NASDAQ:CTSO)

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

CTSO Stock Price History

CTSO Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
CTSO Apr 2024 2.500 call
Q4 2023 Cytosorbents Corp Earnings Call
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Recap: CytoSorbents Q4 Earnings
Cytosorbents earnings preview: what to expect
CTSO Mar 2024 2.500 call
Cytosorbents Corp
CytoSorbents Stock (NASDAQ:CTSO) Insider Trades
CytoSorbents just downgraded at H.C. Wainwright, here's why
What To Know About HC Wainwright & Co.'s Downgrade of CytoSorbents
See More Headlines
Receive CTSO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytosorbents and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
3/28/2024
Next Earnings (Estimated)
5/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:CTSO
Employees
198
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.50
High Stock Price Target
$4.00
Low Stock Price Target
$1.00
Potential Upside/Downside
+163.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-28,510,000.00
Pretax Margin
-80.67%

Debt

Sales & Book Value

Annual Sales
$36.35 million
Book Value
$0.52 per share

Miscellaneous

Free Float
49,896,000
Market Cap
$51.58 million
Optionable
Optionable
Beta
0.58
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Phillip P. Chan M.D. (Age 54)
    Ph.D., CEO & Director
    Comp: $541.93k
  • Mr. Vincent J. Capponi M.S. (Age 66)
    President & COO
    Comp: $452.62k
  • Ms. Kathleen P. Bloch CPAMs. Kathleen P. Bloch CPA (Age 69)
    M.B.A., Chief Financial Officer
    Comp: $395.43k
  • Dr. Efthymios N. Deliargyris FACC (Age 56)
    FESC, FSCAI, M.D., Chief Medical Officer
    Comp: $463.15k
  • Ms. Terri Anne Powers M.B.A.
    Vice President of Investor Relations & Corporate Communications
  • Dr. Christian Steiner M.D.
    Executive Vice President of Sales & Marketing
  • Mr. Christopher Cramer M.B.A.
    M.S., Senior Vice President of Business Development
  • Dr. Irina B. Kulinets Ph.D. (Age 69)
    Senior Vice President of Global Regulatory Affairs
  • Jodi Hoover
    Executive
  • Dr. Robert H. Bartlett M.D. (Age 85)
    Co-Chairman of Cardiac Surgery Advisory Board & Consultant
    Comp: $54k

CTSO Stock Analysis - Frequently Asked Questions

Should I buy or sell Cytosorbents stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytosorbents in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CTSO shares.
View CTSO analyst ratings
or view top-rated stocks.

What is Cytosorbents' stock price target for 2024?

2 analysts have issued 1 year price targets for Cytosorbents' shares. Their CTSO share price targets range from $1.00 to $4.00. On average, they anticipate the company's stock price to reach $2.50 in the next year. This suggests a possible upside of 163.2% from the stock's current price.
View analysts price targets for CTSO
or view top-rated stocks among Wall Street analysts.

How have CTSO shares performed in 2024?

Cytosorbents' stock was trading at $1.11 on January 1st, 2024. Since then, CTSO shares have decreased by 14.4% and is now trading at $0.95.
View the best growth stocks for 2024 here
.

When is Cytosorbents' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our CTSO earnings forecast
.

How were Cytosorbents' earnings last quarter?

Cytosorbents Co. (NASDAQ:CTSO) announced its earnings results on Thursday, November, 4th. The medical research company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.03. The medical research company earned $9.76 million during the quarter, compared to analyst estimates of $9.96 million. Cytosorbents had a negative trailing twelve-month return on equity of 120.24% and a negative net margin of 78.43%. During the same quarter last year, the business earned ($0.02) EPS.

What is Phillip Chan's approval rating as Cytosorbents' CEO?

11 employees have rated Cytosorbents Chief Executive Officer Phillip Chan on Glassdoor.com. Phillip Chan has an approval rating of 26% among the company's employees. This puts Phillip Chan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 74.0% of employees surveyed would recommend working at Cytosorbents to a friend.

What other stocks do shareholders of Cytosorbents own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytosorbents investors own include Rekor Systems (REKR), Advanced Micro Devices (AMD), Micron Technology (MU), Gilead Sciences (GILD), Pfizer (PFE), AbbVie (ABBV), Inovio Pharmaceuticals (INO), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).

Who are Cytosorbents' major shareholders?

Cytosorbents' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Granahan Investment Management LLC (8.14%), Skylands Capital LLC (7.32%), Avenir Corp (6.87%), Neuberger Berman Group LLC (4.05%), Neuberger Berman Group LLC (4.05%) and Sargent Investment Group LLC (2.94%). Insiders that own company stock include Al Kraus, Alan D Sobel, Edward Raymond Jones, Jiny Kim, Kathleen P Bloch, Michael G Bator, Phillip P Chan and Vincent Capponi.
View institutional ownership trends
.

How do I buy shares of Cytosorbents?

Shares of CTSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CTSO) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners